Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Linperlisib in B-Cell Malignancies
NCT03757000Phase 1Unknown
- Sponsor
- Yingli Pharma
- Start
- Dec 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of linperlisib in B cell lymphoma and chronic lymphocytic leukemia (CLL), sponsored by Yingli Pharma. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events. Status: unknown.
02
Drugs
linperlisib
03
Conditions
B cell lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03757000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03757000.